Arcus halts Gilead-partnered late-stage trial for lung cancer drug

Arcus Biosciences (RCUS) stock drops as the company halts a late-stage trial for a lung cancer drug developed with Gilead ...
Fierce Biotech

Gilead loosens ties to Arcus after TIGIT dream finally ends in phase 3 failure

Gilead Sciences and Arcus Biosciences’ domvanalimab, one of the last anti-TIGIT antibodies still standing, has failed another ...
Zacks Investment Research on MSN

Arcus Biosciences, Inc. (RCUS) may report negative earnings: Know the trend ahead of next week's release

Wall Street expects a year-over-year increase in earnings on lower revenues when Arcus Biosciences, Inc. (RCUS) reports ...

Arcus Biosciences Discontinues Lung Cancer Trial With Gilead

Arcus Biosciences is discontinuing a phase 3 lung cancer trial it was conducting with Gilead Sciences. Arcus, an oncology company, said Monday it was ending the trial due to futility, meaning it doesn ...

Arcus Biosciences (RCUS) Is Up 5.2% After Lung Trial Futility Results And Gilead Option Shift

Arcus Biosciences and Gilead Sciences recently discontinued the Phase 3 STAR-121 and Phase 2 EDGE-Lung studies for domvanalimab and zimberelimab in metastatic non-small cell lung cancer after a ...

Core Silver and Arcus Development Group Enter into a Binding Letter of Intent for a Business Combination Transaction and Sign a Definitive Option Agreement for the Touleary Project

VANCOUVER, BC / ACCESS Newswire / April 27, 2026 / Core Silver Corp. (CSE:CC)(FSE:8ZR)(OTCQB:CCOOF) ("Core Silver") and Arcus Development Group Inc. (TSXV:ADG) ("Arcus", and together with Core Silver, ...

Arcus Biosciences: TIGIT In The Rearview Mirror, But Market Pricing A Bit Too Aggressively For Now

Arcus Biosciences remains resilient, rising over 50% since my last 'Buy' rating despite setbacks in its anti-TIGIT ...
BioSpace

Gilead, Arcus tumble again in TIGIT, triggering 2 trial culls

The Phase 3 failure has prompted Gilead Sciences and Arcus Biosciences to terminate a mid-stage study of their TIGIT asset in ...
Business Insider

Arcus Biosciences spikes 99% on reports of $10 billion Gilead partnership

Shares of cancer drug developer Arcus Biosciences skyrocketed as much as 99% in Thursday trading after Bloomberg reported biotech firm Gilead may buy a stake in the company. Alphabet owns the largest ...
Nasdaq

Arcus Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides a Pipeline Update

At least two additional data presentations for casdatifan are expected in 2026: updated data for casdatifan plus cabozantinib and initial data in early-line kidney cancer In addition to the ongoing ...
The Motley Fool

Arcus Biosciences President Sells $2 Million as Stock Delivers 48% Annual Return

82,997 shares were sold indirectly on Dec. 4, 2025, for a transaction value of ~$2.1 million based on a weighted average sale price of $24.71 per share. The sale represented 5.91% of total holdings, ...
MM&M

Gilead invests $320M in Arcus to increase stake to 33%

Gilead Sciences and Arcus Biosciences said they’ve expanded their three-year-old collaboration. An equity stake in Arcus, board seat for Gilead’s commercial chief and a streamlined immuno-oncology ...